EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

New-Onset Diabetes After COVID-19

Sun H Kim iD, Ipsa Arora, Daniel S Hsia iD, William C Knowler iD, Erin LeBlanc iD, Eleftherios Mylonakis iD, Richard Pratley iD, Anastassios G Pittas iD

The Journal of Clinical Endocrinology & Metabolism · 18.10.2023 · 108 (11) · e1164-e1174

DOI: 10.1210/clinem/dgad284 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 19.05.2023. Verfasst von Sun H Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Gerontology and Metabolism, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. Hauptthemen laut MEDLINE: COVID-19, Diabetes Mellitus, Hyperglycemia, Insulin Resistance. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is evidence suggesting that infection with SARS-CoV-2 can lead to several long-term sequelae including diabetes. This mini-review examines the rapidly evolving and conflicting literature on new-onset diabetes after COVID-19, which we term NODAC. We searched PubMed, MEDLINE, and medRxiv from inception until December 1, 2022, using Medical Subject Headings (MeSH) terms and free text words including “COVID-19,” “SARS-CoV-2,” “diabetes,” “hyperglycemia,” “insulin resistance,” and “pancreatic β-cell.” We also supplemented searches by examining reference lists from retrieved articles. Current evidence suggests that COVID-19 increases the risk of developing diabetes, but the attributable risk is uncertain because of limitations of study designs and the evolving nature of the pandemic, including new variants, widespread population exposure to the virus, diagnostic options for COVID-19, and vaccination status. The etiology of diabetes after COVID-19 is likely multifactorial and includes factors associated with host characteristics (eg, age), social determinants of health (eg, deprivation index), and pandemic-related effects both at the personal (eg, psychosocial stress) and the societal-community level (eg, containment measures). COVID-19 may have direct and indirect effects on pancreatic β-cell function and insulin sensitivity related to the acute infection and its treatment (eg, glucocorticoids); autoimmunity; persistent viral residency in multiple organs including adipose tissue; endothelial dysfunction; and hyperinflammatory state. While our understanding of NODAC continues to evolve, consideration should be given for diabetes to be classified as a post-COVID syndrome, in addition to traditional classifications of diabetes (eg, type 1 or type 2), so that the pathophysiology, natural history, and optimal management can be studied.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Diabetes MellitusHyperglycemiaInsulin ResistanceHumansSARS-CoV-2Risk Factors

Stichwörter der Autor:innen

COVID-19SARS-CoV-2diabetes mellitushyperglycemiainsulin resistancepancreatic β-cell

Autor:innen und Institutionen

  • Division of Endocrinology, Gerontology and Metabolism, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Tufts Medical Center, Boston, MA 02111, USA.
  • Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA 70808, USA.
  • National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, AZ 85016, USA.
  • Center for Health Research, Kaiser Permanente, Portland, OR 97227, USA.
  • Department of Medicine, Houston Methodist Hospital, Houston, TX 77030, USA.

ORCID-Profile: Sun H Kim, Daniel S Hsia, William C Knowler, Erin LeBlanc, Eleftherios Mylonakis, Richard Pratley, Anastassios G Pittas

Förderung

  • NIH

Zitieren

APA

Kim, S. H., Arora, I., Hsia, D. S., Knowler, W. C., LeBlanc, E., Mylonakis, E., Pratley, R., & Pittas, A. G. (2023). New-Onset Diabetes After COVID-19. The Journal of Clinical Endocrinology & Metabolism, 108(11), e1164-e1174. https://doi.org/10.1210/clinem/dgad284

Vancouver

Kim SH, Arora I, Hsia DS, Knowler WC, LeBlanc E, Mylonakis E, et al. New-Onset Diabetes After COVID-19. The Journal of Clinical Endocrinology & Metabolism. 2023;108(11):e1164-e1174. doi:10.1210/clinem/dgad284

BibTeX
@article{Kim2023,
  author = {Kim, Sun H and Arora, Ipsa and Hsia, Daniel S and Knowler, William C and LeBlanc, Erin and Mylonakis, Eleftherios and Pratley, Richard and Pittas, Anastassios G},
  title = {New-Onset Diabetes After COVID-19},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  volume = {108},
  number = {11},
  pages = {e1164--e1174},
  doi = {10.1210/clinem/dgad284}
}
Kostenlos starten →